Inovio Biomedical Corporation (AMEX: INO)Inovio Biomedical Corporation (AMEX: INO) has their focus on developing multiple DNA-based immunotherapies. The company is known as a leading developer of human applications of electroporation using brief, controlled electrical pulses to increase cellular uptake of a useful biopharmaceutical. Inovio’s DNA delivery technology has demonstrated the ability to substantially increase gene expression and immune responses from DNA vaccines. For further information, visit the Company’s web site at www.inovio.com.
- 18 years ago
QualityStocks
Inovio Biomedical Corporation (AMEX: INO)
Tags Rodman & Renshaw
Related Post
-
QualityStocksNewsBreaks – Regentis Biomaterials Ltd. (NYSE American: RGNT) Moves GelrinC Closer to Regulatory and Commercial Milestones
Regentis Biomaterials (NYSE American: RGNT) is advancing its GelrinC hydrogel-based cartilage regeneration technology toward key clinical, regulatory…
-
Wrap Technologies Inc. (NASDAQ: WRAP) Positions Non-Lethal Innovation at the Center of Public Safety Reform
WRAP offerings illustrate a broader industry trend toward building connected ecosystems rather than standalone products.…
-
Brownfield Gold Projects Could Hold an Edge in Today’s Permitting Environment
Disseminated on behalf of Lahontan Gold Corp. (TSX.V: LG) (OTCQB: LGCXF) and may include paid advertising.…